TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35345262

Group type: EXPERIMENTAL
Intervention: New multivariate predictive model for predicting aortic root diameter
Number of subjects: 943

Group type: COMPARATOR
Intervention: Measured AoR diameter
Number of subjects: 943
Study: 35346046

Group type: EXPERIMENTAL
Intervention: Nexfin® (non-invasive finger-cuff technology)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: NIBP (oscillometric, non-invasive blood pressure measurement)
Number of subjects: 60

Group type: COMPARATOR
Intervention: IAP (invasive arterial pressure)
Number of subjects: 60
Study: 35346070

Group type: EXPERIMENTAL
Intervention: Selective internal radiation therapy (SIRT) with yttrium-90, target mean dose to tumor is ≥ 150 Gy.
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Selective internal radiation therapy (SIRT) with yttrium-90
Number of subjects: 100
Study: 35346138

Group type: EXPERIMENTAL
Intervention: Qualitative inquiry into lived experiences post-hospitalization for COVID-19
Number of subjects: 150
Study: 35346165

Group type: EXPERIMENTAL
Intervention: Moderate albuminuria (UACR 30-300 mg/g)
Number of subjects: 9170

Group type: EXPERIMENTAL
Intervention: Severe albuminuria (UACR > 300 mg/g)
Number of subjects: 9170

Group type: EXPERIMENTAL
Intervention: eGFR < 60 mL/min/1.73 m²
Number of subjects: 9170
Study: 35346219

Group type: EXPERIMENTAL
Intervention: Opioid Medication Therapy (OMT)
Number of subjects: 263
Study: 35346244

Group type: EXPERIMENTAL
Intervention: Multi-use trails (4-7 km in length) constructed between 2010 and 2012.
Number of subjects: 37901
Study: 35346256

Group type: EXPERIMENTAL
Intervention: Weight loss in MUO after 3 months
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Weight loss in MHO after 3 months
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Weight loss in MUO after 21 months
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Weight loss in MHO after 21 months
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Long-term HDL-cholesterol improvement in MUO
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Long-term triglycerides improvement in MUO
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Quality of Life (QoL) in MUO
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Quality of Life (QoL) in MHO
Number of subjects: 143
Study: 35346458

Group type: EXPERIMENTAL
Intervention: Aβ pathology at baseline
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Cognitive decline over time
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Change in cognition
Number of subjects: 356
Study: 35346720

Group type: EXPERIMENTAL
Intervention: Plasminogen Eyedrops
Number of subjects: 0
Study: 35346837

Group type: EXPERIMENTAL
Intervention: Adaptive deep brain stimulation (aDBS) based on chronic subcortical sensing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chronic subcortical sensing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Implantable pulse generators (IPG) for recording neural activity
Number of subjects: 0
Study: 35346927

Group type: EXPERIMENTAL
Intervention: Adding back- or front-office staff in past 12 months
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Having staff help patients resolve barriers to CRC screening
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Having staff hand out FITs/educate patients
Number of subjects: 39

Group type: COMPARATOR
Intervention: Absence of the three support staff factors
Number of subjects: 39
Study: 35347368

Group type: EXPERIMENTAL
Intervention: Transvaginal prolapse repair with Elevate anterior and posterior
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Transvaginal prolapse repair with Elevate anterior/apical fixation
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Transvaginal prolapse repair with Elevate posterior/apical fixation
Number of subjects: 277
Study: 35347559

Group type: EXPERIMENTAL
Intervention: Glesatinib 700 mg twice daily (micronized V2) with erlotinib 150 mg once daily
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Glesatinib 700 mg twice daily (micronized V2) with docetaxel 75 mg/m2
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Glesatinib (various formulations) plus erlotinib or docetaxel
Number of subjects: 126
Study: 35347997

Group type: EXPERIMENTAL
Intervention: Huawei smartwatch monitoring
Number of subjects: 100
Study: 35348247

Group type: EXPERIMENTAL
Intervention: Self-report questionnaires and clinical signs of bruxism
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Bruxoff® device for recording electromyographic/electrocardiographic data
Number of subjects: 200
Study: 35348445

Group type: EXPERIMENTAL
Intervention: Powered exoskeleton
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 35348754

Group type: EXPERIMENTAL
Intervention: Apatinib (500 mg orally daily)
Number of subjects: 15
Study: 35349025

Group type: EXPERIMENTAL
Intervention: Patient Partner Guide (PPG) - a five-step workbook providing practical tools and resources for clinic QI teams.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Engagement of patient co-investigators in research.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Use of the PPG in clinics undertaking the QI project.
Number of subjects: 20
Study: 35349076

Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 33
Study: 35349129

Group type: EXPERIMENTAL
Intervention: 12 mg of dexamethasone
Number of subjects: 0

Group type: COMPARATOR
Intervention: 6 mg of dexamethasone
Number of subjects: 0
Study: 35349162

Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics (cefazolin)
Number of subjects: 390
Study: 35349186

Group type: EXPERIMENTAL
Intervention: Occupational therapy intervention
Number of subjects: 1142

Group type: COMPARATOR
Intervention: Control groups (usual rehabilitation or occupational therapy care)
Number of subjects: 1142

Group type: COMPARATOR
Intervention: Control groups (waiting list)
Number of subjects: 1142
Study: 35349331

Group type: EXPERIMENTAL
Intervention: Sorafenib (200 mg/m) added to conventional AML chemotherapy
Number of subjects: 72

Group type: COMPARATOR
Intervention: Conventional AML chemotherapy
Number of subjects: 72
Study: 35349380

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 35349466

Group type: EXPERIMENTAL
Intervention: PositiveLinks (PL) mHealth intervention
Number of subjects: 482

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 482
Study: 35349491

Group type: EXPERIMENTAL
Intervention: CIML NK cells infused after lymphodepleting chemotherapy (5 to 10 million cells/kg) followed by systemic IL-2 for 7 doses.
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: CIML NK cells
Number of subjects: 6
Study: 35349631

Group type: EXPERIMENTAL
Intervention: huCART-19
Number of subjects: 20
Study: 35349683

Group type: EXPERIMENTAL
Intervention: Marine oil supplement (2 g/d for 28-30 days)
Number of subjects: 23
Study: 35350054

Group type: EXPERIMENTAL
Intervention: Asians (N = 317)
Number of subjects: 1253

Group type: EXPERIMENTAL
Intervention: Blacks (N = 158)
Number of subjects: 1253

Group type: EXPERIMENTAL
Intervention: Whites (N = 736)
Number of subjects: 1253

Group type: EXPERIMENTAL
Intervention: Other races (N = 42)
Number of subjects: 1253

Group type: COMPARATOR
Intervention: Asians compared to Blacks
Number of subjects: 1253

Group type: COMPARATOR
Intervention: Asians compared to Whites
Number of subjects: 1253

Group type: COMPARATOR
Intervention: Whites compared to Blacks
Number of subjects: 1253
Study: 35350411

Group type: EXPERIMENTAL
Intervention: Nutritional education
Number of subjects: 221

Group type: COMPARATOR
Intervention: Control (no nutritional education)
Number of subjects: 221
Study: 35350582

Group type: EXPERIMENTAL
Intervention: Robot-assisted reaching and hand-to-mouth movements, 12 sessions of 40 minutes each, 3 times per week
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Robot-assisted reaching and hand-to-mouth movements
Number of subjects: 19
Study: 35350834

Group type: EXPERIMENTAL
Intervention: First dose of the COVID-19 vaccine
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Second dose of the COVID-19 vaccine
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both doses of the COVID-19 vaccine
Number of subjects: 100
Study: 35350938

Group type: EXPERIMENTAL
Intervention: Radioimmunotherapy (RIT) targeting CD33, CD45, or CD66
Number of subjects: 0
Study: 35350948

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg)
Number of subjects: 0
Study: 35351093

Group type: EXPERIMENTAL
Intervention: Continuous care intervention (CCI)
Number of subjects: 242

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 242
Study: 35351100

Group type: EXPERIMENTAL
Intervention: Caregivers (female)
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Caregivers (male)
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Positive depression screening
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Perceived burden (female caregivers)
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Domestic help (male caregivers)
Number of subjects: 218
Study: 35351106

Group type: EXPERIMENTAL
Intervention: Pain Science Education (PSE)
Number of subjects: 15
Study: 35351181

Group type: EXPERIMENTAL
Intervention: p-tau217 alone
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Combination of p-tau217 with hippocampal volume, cognition, and APOE genotype
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Combination of p-tau217 and cognition
Number of subjects: 110
Study: 35351214

Group type: EXPERIMENTAL
Intervention: Restrictive intravenous fluid protocol
Number of subjects: 124

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 124
Study: 35351714

Group type: EXPERIMENTAL
Intervention: Mobile health-based programme for HIV and TB integration
Number of subjects: 60
Study: 35351731

Group type: EXPERIMENTAL
Intervention: Combined diagnostic accuracy study
Number of subjects: 0
Study: 35351823

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve implantation (TAVI) for rheumatic AS
Number of subjects: 105

Group type: COMPARATOR
Intervention: Transcatheter aortic valve implantation (TAVI) for degenerative AS
Number of subjects: 105
Study: 35352025

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 35352097

Group type: EXPERIMENTAL
Intervention: Electronic dose monitoring (EDM) for ART adherence
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: ART adherence
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Reduced ART adherence
Number of subjects: 198
Study: 35352102

Group type: EXPERIMENTAL
Intervention: Daily coformulated tenofovir disoproxil fumarate and emtricitabine for HIV prevention
Number of subjects: 9596
Study: 35352313

Group type: EXPERIMENTAL
Intervention: Guselkumab 100 mg every 4 or 8 weeks
Number of subjects: 739

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 739
Study: 35352512

Group type: EXPERIMENTAL
Intervention: sintilimab (200 mg IV every 2 weeks for three cycles) plus hypofractionated radiotherapy (5 Gy × 5)
Number of subjects: 0
Study: 35352564

Group type: EXPERIMENTAL
Intervention: Novel Observation Group Criteria of the ESC 0/1-Hour Algorithm
Number of subjects: 0
Study: 35352604

Group type: EXPERIMENTAL
Intervention: Tack Endovascular System
Number of subjects: 233
Study: 35352766

Group type: EXPERIMENTAL
Intervention: Albuterol and ipratropium bromide delivered via pressurized metered-dose inhaler with holding chamber and systemic corticosteroids
Number of subjects: 60
Study: 35352882

Group type: EXPERIMENTAL
Intervention: Well-anticoagulated atrial fibrillation patients
Number of subjects: 9503

Group type: COMPARATOR
Intervention: OAC-naïve AF cohort
Number of subjects: 9503
Study: 35353154

Group type: COMPARATOR
Intervention: Dual pathway inhibition (DPI) with a P2Y12 inhibitor (clopidogrel or ticagrelor) and a vascular dose of rivaroxaban
Number of subjects: 40

Group type: COMPARATOR
Intervention: DAPT with a P2Y12 inhibitor (clopidogrel or ticagrelor)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Ticagrelor-based DPI
Number of subjects: 40
Study: 35353197

Group type: EXPERIMENTAL
Intervention: Risk scoring system based on four independent variables (hemodynamic instability, involvement of the small bowel, paper-thin wall pattern, no stratified enhancement pattern)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Risk scoring system validated in external cohort
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Risk scoring system categorized patients into low risk (score: 0, 1), high risk (score: 2-3), and very high risk (score: 4-7)
Number of subjects: 205
Study: 35353219

Group type: EXPERIMENTAL
Intervention: IDH305 at doses 75-750 mg twice daily
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: IDH305
Number of subjects: 41
Study: 35353229

Group type: EXPERIMENTAL
Intervention: Frequency of family meals
Number of subjects: 1964

Group type: EXPERIMENTAL
Intervention: Frequency of family breakfast
Number of subjects: 1964
Study: 35353263

Group type: EXPERIMENTAL
Intervention: Remission (ASDAS-CRP)
Number of subjects: 969

Group type: EXPERIMENTAL
Intervention: Low disease activity (ASDAS-CRP)
Number of subjects: 969

Group type: EXPERIMENTAL
Intervention: Drug switching
Number of subjects: 969

Group type: EXPERIMENTAL
Intervention: MASES and BASMI scores in drug switchers
Number of subjects: 969
Study: 35353962

Group type: EXPERIMENTAL
Intervention: Primaquine at a total dose of 7.0 mg per kilogram
Number of subjects: 254
Study: 35354274

Group type: EXPERIMENTAL
Intervention: Avelumab, dosage not specified, duration not specified
Number of subjects: 0
Study: 35354298

Group type: EXPERIMENTAL
Intervention: Cardioembolism
Number of subjects: 1015

Group type: EXPERIMENTAL
Intervention: Thrombectomy passes in cardioembolism patients
Number of subjects: 1015
Study: 35354310

Group type: EXPERIMENTAL
Intervention: Hydrogel-based autologous chondrocyte implantation (ACI)
Number of subjects: 100
Study: 35354442

Group type: EXPERIMENTAL
Intervention: PLUSS model implementation
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Parental training
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Training for preschool professionals
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Screening procedure
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Child-related outcomes
Number of subjects: 130
Study: 35354445

Group type: EXPERIMENTAL
Intervention: Comprehensive menstrual health and hygiene (MHH) intervention integrated within community-based sexual and reproductive health (SRH) service
Number of subjects: 9
Study: 35354456

Group type: EXPERIMENTAL
Intervention: Implementation strategies for PrEP integration into family planning services
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Private, youth-friendly clinic
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Adoption of PrEP delivery among non-study staff
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Behavioral intervention for FP providers
Number of subjects: 1000
Study: 35354482

Group type: EXPERIMENTAL
Intervention: CPAP 20 cmH2O
Number of subjects: 38

Group type: COMPARATOR
Intervention: Passive leg raise maneuver
Number of subjects: 38
Study: 35354561

Group type: EXPERIMENTAL
Intervention: Vision Impairment in Low Luminance (VILL-33) questionnaire
Number of subjects: 716

Group type: COMPARATOR
Intervention: Advanced AMD stage
Number of subjects: 716
Study: 35354581

Group type: EXPERIMENTAL
Intervention: HTN+/T2D+
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HTN+/T2D-
Number of subjects: 0

Group type: COMPARATOR
Intervention: HTN-/T2D-
Number of subjects: 0

Group type: COMPARATOR
Intervention: ADNI non-Hispanic White participants
Number of subjects: 0

Group type: COMPARATOR
Intervention: ADNI + NACC Hispanic cohort
Number of subjects: 0
Study: 35354626

Group type: EXPERIMENTAL
Intervention: Stool FIT plus urine VOC
Number of subjects: 1915

Group type: COMPARATOR
Intervention: Stool FIT alone
Number of subjects: 1915

Group type: EXPERIMENTAL
Intervention: Economic evaluation of FIT + VOC
Number of subjects: 1915
Study: 35354640

Group type: EXPERIMENTAL
Intervention: Collaborative nursing care intervention through Participatory Action Research activities
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care dynamics
Number of subjects: 0
Study: 35354660

Group type: EXPERIMENTAL
Intervention: GRACE risk score
Number of subjects: 5015

Group type: EXPERIMENTAL
Intervention: Optimal guideline-recommended care
Number of subjects: 5015

Group type: COMPARATOR
Intervention: Intermediate-risk patients
Number of subjects: 5015

Group type: COMPARATOR
Intervention: High-risk patients
Number of subjects: 5015
Study: 35354659

Group type: EXPERIMENTAL
Intervention: CCTA in South Asian patients
Number of subjects: 170

Group type: COMPARATOR
Intervention: CCTA in Caribbean black patients
Number of subjects: 170
Study: 35354808

Group type: EXPERIMENTAL
Intervention: Devimistat in combination with high dose cytarabine and mitoxantrone
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Maintenance devimistat
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Unplanned post-hoc analysis
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: RNA sequencing data
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Devimistat
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Pharmacological or genetic inhibition of mitochondrial fission or autophagy
Number of subjects: 48
Study: 35355147

Group type: EXPERIMENTAL
Intervention: Regional citrate anticoagulation (RCA) during CRRT
Number of subjects: 11
Study: 35355397

Group type: EXPERIMENTAL
Intervention: Thalassaemia patients (TDT and TIT)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Thalassaemia patients (TIT)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Thalassaemia presence (TDT or TIT)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Matched cohort with no history of thalassaemia
Number of subjects: 137
Study: 35355438

Group type: EXPERIMENTAL
Intervention: Gemcitabine plus cisplatin (GP) induction chemotherapy
Number of subjects: 0
Study: 35355447

Group type: EXPERIMENTAL
Intervention: Daprodustat (6-mg single dose)
Number of subjects: 0
Study: 35355714

Group type: EXPERIMENTAL
Intervention: Psilocybin (medium-high doses)
Number of subjects: 28
Study: 35355964

Group type: EXPERIMENTAL
Intervention: COVID-19 patients with myocardial damage
Number of subjects: 19
Study: 35355991

Group type: EXPERIMENTAL
Intervention: Combination therapy of melatonin and DADA (diisopropylamine dichloroacetate)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Melatonin alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: DADA alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination therapy of melatonin and DADA
Number of subjects: 0
Study: 35356149

Group type: EXPERIMENTAL
Intervention: Energy balance modeling displayed on weight graphs combined with a wrist-worn bite counting sensor
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional online behavioral weight loss program
Number of subjects: 0
Study: 35356197

Group type: EXPERIMENTAL
Intervention: CD19-CAR T cell therapy (tisagenlecleucel or on an institutional clinical trial)
Number of subjects: 38
Study: 35356225

Group type: EXPERIMENTAL
Intervention: Pulmonary branch of vagus nerve preservation group (Group A)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Conventional surgical treatment group (Group B)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 158
Study: 35356262

Group type: EXPERIMENTAL
Intervention: Pyrotinib-based therapy
Number of subjects: 76
Study: 35356508

Group type: EXPERIMENTAL
Intervention: Letrozole 5 mg/day
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 35356551

Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard parametric models
Number of subjects: 0

Group type: COMPARATOR
Intervention: Piecewise and cubic spline models
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mixture cure, parametric mixture, and landmark response models
Number of subjects: 0
Study: 35356713

Group type: EXPERIMENTAL
Intervention: Vortioxetine
Number of subjects: 737
Study: 35356726

Group type: EXPERIMENTAL
Intervention: Experimental infant formula (EF) enriched with milk fat globule membrane (MFGM), long-chain polyunsaturated fatty acids (LC-PUFAs), and synbiotics
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Experimental infant formula (EF)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Standard infant formula (SF)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Breastfed (BF)
Number of subjects: 108
Study: 35356974

Group type: EXPERIMENTAL
Intervention: Cancer stem cells (CSCs) frequency
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Higher CSC frequency in locally advanced disease
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Lower CSC frequency in early-stage patients
Number of subjects: 35
Study: 35357027

Group type: EXPERIMENTAL
Intervention: Dostarlimab (1, 3 or 10 mg/kg)
Number of subjects: 546

Group type: EXPERIMENTAL
Intervention: Dostarlimab
Number of subjects: 546
Study: 35357219

Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy (CRT) with Implantable Defibrillator
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cardiac Resynchronization Therapy (CRT) without Implantable Defibrillator
Number of subjects: 0
Study: 35357290

Group type: EXPERIMENTAL
Intervention: Proton radiation with FLASH RT adaptation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: α-particle radiation therapies including brachytherapy, proton-boron capture therapy (PBCT), and boron-neutron capture therapy (BNCT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carbon ion therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combinatorial immune-based therapies with high-LET RT
Number of subjects: 0
Study: 35357325

Group type: EXPERIMENTAL
Intervention: Mindfulness mobile application (Headspace) used daily for 30 days (up to 10 minutes a day)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 140
Study: 35357436

Group type: EXPERIMENTAL
Intervention: Endometrial compaction (measured as percentage difference in endometrial thickness between T1 and T2)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Endometrial compaction >0%
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Endometrial compaction ≥5%
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Endometrial compaction ≥10%
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Endometrial compaction ≥15%
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Endometrial compaction ≥20%
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Sub-analysis by FET protocol type (programmed vs modified natural)
Number of subjects: 186